<code id='2D59331452'></code><style id='2D59331452'></style>
    • <acronym id='2D59331452'></acronym>
      <center id='2D59331452'><center id='2D59331452'><tfoot id='2D59331452'></tfoot></center><abbr id='2D59331452'><dir id='2D59331452'><tfoot id='2D59331452'></tfoot><noframes id='2D59331452'>

    • <optgroup id='2D59331452'><strike id='2D59331452'><sup id='2D59331452'></sup></strike><code id='2D59331452'></code></optgroup>
        1. <b id='2D59331452'><label id='2D59331452'><select id='2D59331452'><dt id='2D59331452'><span id='2D59331452'></span></dt></select></label></b><u id='2D59331452'></u>
          <i id='2D59331452'><strike id='2D59331452'><tt id='2D59331452'><pre id='2D59331452'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:961
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In